Publications

Cazelles, R; Shukla, RP; Ware, RE; Vinks, AA; Ben-Yoav, H. Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9.

Dong, M; McGann, PT. Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. Clinical Pharmacology and Therapeutics. 2021; 109:73-81.

Girdwood, ST; Kaplan, J; Vinks, AA. Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children. Journal of hospital medicine (Online). 2021; 16:35-37.

McPhail, BT; Emoto, C; Butler, D; Fukuda, T; Akinbi, H; Vinks, AA. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. Journal of Clinical Pharmacology. 2021.

Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA. Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacokinetics. 2021; 60:249-259.

Neely, MN; Vinks, AA. Roger W. Jelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model-Based Target Controlled Individualized Dosing. Clinical Pharmacology and Therapeutics. 2021; 109:22-24.

Peck, RW; Shahin, MH; Vinks, AA. Precision Dosing: The Clinical Pharmacology of Goldilocks. Clinical Pharmacology and Therapeutics. 2021; 109:11-14.

Sebold, AJ; Day, AM; Ewen, J; Adamek, J; Byars, A; Cohen, B; Kossoff, EH; Mizuno, T; Ryan, M; Sievers, J; et al. Sirolimus Treatment in Sturge-Weber Syndrome. Pediatric Neurology. 2021; 115:29-40.

Soul, JS; Bergin, AM; Stopp, C; Hayes, B; Singh, A; Fortuno, CR; O'Reilly, D; Krishnamoorthy, K; Jensen, FE; Rofeberg, V; et al. A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. Annals of Neurology. 2021; 89:327-340.

van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.

Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.

Wright, KD; Yao, X; London, WB; Kao, PC; Gore, L; Hunger, S; Geyer, R; Cohen, KJ; Allen, JC; Katzenstein, HM; et al. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatric Blood and Cancer. 2021; 68.

Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics. 2021.

Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Cardiovascular Drugs and Therapy. 2021.

Zhao, J; Sharat, C; Mehta, PA; Mizuno, K; Vinks, AA; Setchell, KD R. Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. Journal of Applied Laboratory Medicine. 2021.